Abstracts Archive - Page 1899 of 2607 - ACR Meeting Abstracts

Abstract Number: 416 • 2015 ACR/ARHP Annual Meeting
Prospective, Standardized, Longitudinal Assessment Reveals Higher Prevalence of Extracutaneous Manifestations in a Pediatric Localized Scleroderma Cohort
Kaveh Ardalan, Christina Kelsey and Kathryn S. Torok, Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
Background/Purpose: Localized scleroderma (LS) is an autoimmune condition whose hallmarks are progressive skin fibrosis and atrophy. However, LS is unique among skin diseases for its…
Abstract Number: 417 • 2015 ACR/ARHP Annual Meeting
Gender Differences in Pediatric Localized Scleroderma: Clinical and Patient-Reported Outcomes
Kaveh Ardalan¹, Nicole Hershey¹, Jonathan Yabes², Eveline Wu³, Suzanne C. Li⁴, Robert C. Fuhlbrigge⁵, C. Egla Rabinovich⁶, Kathryn S. Torok¹ and The CARRA Registry Investigators, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³Pediatrics, University of North Carolina - Chapel Hill, Chapel Hill, NC, ⁴Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ⁵Program in Rheumatology, Division of Immunology, Boston Children’s Hospital, Boston, MA, ⁶Pediatric Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: Localized scleroderma (LS) is an autoimmune disease of the skin and underlying tissue that leads to progressive fibrosis and disability in growing children. Pediatric…
Abstract Number: 418 • 2015 ACR/ARHP Annual Meeting
Relationship of Race, Ethnicity, and Outcomes in Pediatric Localized Scleroderma: Possible Differences in Disease Activity
Kaveh Ardalan¹, Nicole Hershey¹, Jonathan Yabes², Kathryn S. Torok¹ and The CARRA Registry Investigators, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Pediatric localized scleroderma (LS) is an autoimmune skin and soft tissue disease that causes morbidity via progressive skin fibrosis and extracutaneous manifestations (ECMs), such…
Abstract Number: 419 • 2015 ACR/ARHP Annual Meeting
Development and Preliminary Validation of a New Composite Disease Activity Measure for Juvenile Dermatomyositis
Alessandro Consolaro¹, Giulia Camilla Varnier¹, Cristina Ferrari¹, Jaime De Inocencio², Adele Civino³, Marija Jelusic-Drazic⁴, Elena Tsitsami⁵, Jelena Vojinovic⁶, Balahan Makay⁷, Graciela Espada⁸, Clara Malattia¹, Susan Maillard⁹, Alberto Martini¹, Clarissa Pilkington¹⁰, Angelo Ravelli^1,11 and Kiran Nistala¹², ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Hospital 12 de Octubre, Madrid, Spain, ³Ospedale Cardinale G. Panico, Tricase, Italy, ⁴University Hospital Center, Zagreb, Croatia, ⁵First Department of Pediatrics, Athens University Medical School, Athens, Greece, ⁶Faculty of Medicine, University of Nis, Nis, Serbia, ⁷Pediatric Rheumatology, Eylul University, Izmir, Turkey, ⁸Rheumatology Section, Childrens Hosp Ricardo Gutierrez, Buenos Aires, Argentina, ⁹Paediatric Rheumatology, Great Ormond Street Hospital NHS Foundation Trust for Children, London, United Kingdom, ¹⁰Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ¹¹University of Genova, Genova, Italy, ¹²Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Evaluation of the level of disease activity is a fundamental component of the clinical assessment of children with JDM. The global tools that are currently available for the assessment of the overall disease activity in JDM are centered on physician’s evaluation, neglecting parent’s or child’s perception. Furthermore, these instruments are lengthy and complex. There remains the need for a concise and easily administered tool that provides an absolute measure of disease activity for use in future trials in JDM. Aim of…
Abstract Number: 420 • 2015 ACR/ARHP Annual Meeting
Description of the Juvenile Localized Scleroderma Subgroup of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Eveline Y. Wu¹, Suzanne C. Li², Kathryn S. Torok³, Yamini Virkud⁴, Robert C. Fuhlbrigge⁵, C. Egla Rabinovich⁶ and CARRA Registry Investigators, ¹Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Pediatrics, Hackensack University Medical Center, Hackensack, NJ, ³Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ⁴Pediatrics, Massachusetts General Hospital for Children, Boston, MA, ⁵Pediatric Rheumatology, Boston Children's Hospital, Boston, MA, ⁶Pediatric Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: Localized scleroderma (LS) is a chronic inflammatory and fibrosing skin disease. We present baseline data on the juvenile LS (jLS) cohort from the Childhood…
Abstract Number: 421 • 2015 ACR/ARHP Annual Meeting
Clinical Analysis and Outcome of Interstitial Lung Disease with Juvenile Dermatomyositis
Satoshi Sato, Yoji Uejima, Eisuke Suganuma, Tadamasa Takano and Yutaka Kawano, Division of Infectious Diseases and Immunology, Saitama Children's Medical Center, Saitama, Japan
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myositis in children. It is a heterogeneous disease and clinical manifestations range from a relatively…
Abstract Number: 422 • 2015 ACR/ARHP Annual Meeting
Mood Disorder Is Highly Prevalent in a Multi-Ethnic Urban Pediatric Lupus Cohort
Tamar Rubinstein^1,2, Dawn Wahezi^1,2, Jay Mehta^3,4, Norman Ilowite^3,5, Debbie Rybak⁶, Jordan Brodsky⁶, Nicole Jordan⁶, Ruth Stein^5,7 and Chaim Putterman⁶, ¹Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ³Division of Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁴Division of Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ⁶Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁷Pediatrics, Children's Hospital at Montefiore, Bronx, NY
Background/Purpose: While mood disorder, most commonly manifesting as depression and anxiety symptoms, is often reported in pediatric lupus patients, prevalence rates vary widely. Many published…
Abstract Number: 423 • 2015 ACR/ARHP Annual Meeting
Institutional and Regional Variation in Childhood SLE 30-Day Hospital Readmission Rates: A Comparative Effectiveness Research Using the Pediatric Health Information System Database
Breanna Beltz¹, Mohammad Shah², Mary Toth³ and Moussa El-Hallak⁴, ¹Hiram College, Akron, OH, ²Patient Safety and Quality Services, Akron Children's Hospital, Akron, OH, ³Rheumatology, Akron Children's Hospital, Akron, OH, ⁴Dept of Pediatric Rheumatology, Akron Children's Hospital, Akron, OH
Background/Purpose: Early hospital readmission is emerging as an indicator of care quality. The reported 30-day hospital readmission (30-DHR) rate for pediatric patients is 6.5%. However,…
Abstract Number: 424 • 2015 ACR/ARHP Annual Meeting
Magnetic Resonance and Echocardiographic Strain Rate Imaging for the Early Detection of Cardiac Involvement in Juvenile Systemic Sclerosis
Francesco Zulian¹, Marta Balzarin¹ and Elena Reffo, Biagio Castaldi, Giorgia Martini, Alessandra Meneghel, Ornella Milanesi, ¹Department of Pediatrics, University of Padua, Padua, Italy
Background/Purpose: Cardiac involvement is one of the worst prognostic factors in JSSc. The diagnosis is usually based on clinical symptoms, EKG and conventional echocardiography, but…
Abstract Number: 425 • 2015 ACR/ARHP Annual Meeting
Impact of in Utero Hydroxychloroquine Exposure on Age of Onset of Cutaneous Neonatal Lupus
Julie Barsalou¹, Nathalie Costedoat-Chalumeau², Cesar Fors-Nieves³, Ummara Shah⁴, Patrick Brown⁵, Carl Laskin⁶, Nathalie Morel², Kateri Levesque⁷, Jill P. Buyon⁸, Earl Silverman⁹ and Peter M. Izmirly¹⁰, ¹Pediatric Rheumatology, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada, ²Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ³Division of Rheumatology, NYU School of Medicine, New York, NY, ⁴Medicine, Strong Memorial Hospital, University of Rochester, Rochester, NY, ⁵University of Toronto, Toronto, ON, Canada, ⁶Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁷Internal Medicine, CHU Ste-Justine, Montréal, QC, Canada, ⁸NYU School of Medicine, New York, NY, ⁹Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ¹⁰Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Biopsy specimens of cutaneous neonatal lupus (cNL) lesions usually show interface dermatitis. Hydroxychloroquine (HCQ) is an effective treatment for interface dermatitis seen in connective…
Abstract Number: 426 • 2015 ACR/ARHP Annual Meeting
The Risk of Hospitalized Infection Following Initiation of Biologic Agents Versus Methotrexate in the Treatment of Juvenile Idiopathic Arthritis
Timothy Beukelman¹, Fenglong Xie², John Baddley³, Lang Chen⁴, Melissa L. Mannion⁵, Kenneth G. Saag⁴, Jie Zhang⁶ and Jeffrey R. Curtis⁴, ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemilogy, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic agents are highly effective for the treatment of juvenile idiopathic arthritis (JIA) but have the potential risk of increased serious infections. Using observational…
Abstract Number: 427 • 2015 ACR/ARHP Annual Meeting
The Impact of Biologic Agent Initiation after 1 Versus 2 Prior Csdmards in Patients with Rheumatoid Arthritis
Dimitrios A. Pappas^1,2, Jenny Griffith³, Chitra Karki², Mei Liu⁴, Joel M. Kremer⁵, Arijit Ganguli³ and Jeffrey D. Greenberg^2,6, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³AbbVie Inc., North Chicago, IL, ⁴352 Turnpike Rd, Corrona, LLC, Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶NYU School of Medicine, New York, NY
Background/Purpose: Patients with Rheumatoid Arthritis (RA) who don’t respond to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) should be treated with biologic agents(1). The objective…
Abstract Number: 428 • 2015 ACR/ARHP Annual Meeting
Use of Rituximab Compared to Anti-TNF Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: 6-Year Follow-up Report from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Boulos Haraoui¹, Frédéric Massicotte¹, Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard³, Diane Sauvageau¹, Édith Villeneuve¹, Louis Coupal¹, Jacques Brown⁴ and Angèle Turcotte⁴, ¹Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Rhumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: The order of use of biologic agents after failing a TNF inhibitor is still a question for debate. Phase III trial data in TNF-IR…
Abstract Number: 429 • 2015 ACR/ARHP Annual Meeting
Treatment Preferences of Patients with Early Rheumatoid Arthritis: A Discrete-Choice Experiment
Glen S. Hazlewood^1,2, Claire Bombardier³, George A. Tomlinson⁴, Carter Thorne⁵, VP Bykerk⁶, Andrew Thompson⁷, Diane Tin⁸ and Deborah Marshall⁹, ¹Medicine, University of Calgary, Calgary, AB, Canada, ²Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, St Joseph's Hlth Ctr, London, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹University of Calgary, Calgary, AB, Canada
Background/Purpose: Treatment choices in early rheumatoid arthritis need to balance benefits, risks, and other considerations such as dosing and monitoring. The objective of this study…
Abstract Number: 430 • 2015 ACR/ARHP Annual Meeting
Adoption of Treat to Target Management in the Context of Achievable Goals and Satisfaction in RA
Peter C. Taylor¹, Juan J Gomez-Reino², Rieke Alten³, Philippe Bertin⁴, Roberto Caporali⁵, Emma Sullivan⁶, Robert Wood⁷, James Piercy⁷, Radu Vasilescu⁸, Dean Spurden⁹ and Jose Alvir¹⁰, ¹Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, ²Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, ³Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁴Rheumatology, CHU Dupuytren, Limoges, France, ⁵University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁶Adelphi Real World, Manchester, United Kingdom, ⁷Adelphi Real World, Macclesfield, United Kingdom, ⁸Medical Affairs, Pfizer Inc, Brussels, Belgium, ⁹Pfizer Inc, Tadworth, United Kingdom, ¹⁰Global Health and Value, Pfizer Inc, New York, NY
Background/Purpose: The approach of setting disease activity targets and adjusting therapy appropriately to achieve the target has been proven to optimize outcomes in Rheumatoid Arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].